Cellergy Pharma Announces Phase I NIAID STTR Grant Award

Cellergy Pharma Announces Phase I NIAID STTR Grant Award for Chimeric Antigen Receptor (CAR) T Cell Therapy for Severe Allergic Diseases

Original Source: Cellergy Pharma

January 5, 2024.

Wilmington, DE – Cellergy Pharma, Inc., a privately held, preclinical stage biotechnology company based in Wilmington, DE, announced it has been awarded a Phase I Small Business Technology Transfer (STTR) award of $300,000 by the National Institute of Allergy and Infectious Diseases (NIAID) todevelop CAR T cell products to treat severe atopic allergic diseases.

Cellergy’s CAR T cells target and eradicate the cells that produce immunoglobulin E (IgE), the key mediator of all atopic diseases.  IgE-mediated diseases include allergic asthma, chronic urticaria, atopic dermatitis, and food allergy.  Atopic diseases have reached epidemic proportions during the past decades in industrialized, and more recently, in developing countries.

“We are grateful for the receipt of this grant award, which will advance the development of our lead CAR T cell product, CP-010, an autologous CAR T cell product that targets membrane IgE.  This award will fund our move into our new research lab at the Innovation Space in Wilmington, DE,” said Dr. Mark Ma, Chief Science Officer of Cellergy Pharma.

“This grant award is an acknowledgement of the importance of Cellergy’s focus to develop CAR T cells for treating severe atopic allergic diseases, including uncontrollable severe allergic asthma,” said Cellergy Pharma President Ronald. P Dudek. “We look forward to conducting this groundbreaking research with our partner, Nemours Children’s Health.”

ABOUT CELLERGY PHARMA

Cellergy Pharma is a privately held biotechnology company that is developing novel CAR T cell products for treating severe atopic allergic diseases.  The company is at the forefront of moving CAR T cells beyond the treatment of cancer, to the treatment of diseases caused by the immune system.  Cellergy’s patented EMPD andFcεRI chimeric antigen receptors target the cells that produce immunoglobulin E, the cause of all atopic allergic diseases. 

https://cellergypharma.com/news

CONTACTS
Company Contact:
Ronald P. Dudek
President
Cellergy Pharma, Inc.
rdudek@cellergypharma.com
https://cellergypharma.com